GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » EV-to-EBIT

ProtoKinetix (ProtoKinetix) EV-to-EBIT : -13.26 (As of Jun. 09, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ProtoKinetix's Enterprise Value is $5.30 Mil. ProtoKinetix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.40 Mil. Therefore, ProtoKinetix's EV-to-EBIT for today is -13.26.

The historical rank and industry rank for ProtoKinetix's EV-to-EBIT or its related term are showing as below:

PKTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.83   Med: 0   Max: 0
Current: -13.26

PKTX's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs PKTX: -13.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ProtoKinetix's Enterprise Value for the quarter that ended in Mar. 2024 was $6.93 Mil. ProtoKinetix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.40 Mil. ProtoKinetix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -5.77%.


ProtoKinetix EV-to-EBIT Historical Data

The historical data trend for ProtoKinetix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix EV-to-EBIT Chart

ProtoKinetix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.81 -3.68 -12.74 -4.49 -15.80

ProtoKinetix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.30 -6.92 -9.16 -15.80 -17.34

Competitive Comparison of ProtoKinetix's EV-to-EBIT

For the Biotechnology subindustry, ProtoKinetix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProtoKinetix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProtoKinetix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ProtoKinetix's EV-to-EBIT falls into.



ProtoKinetix EV-to-EBIT Calculation

ProtoKinetix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.304/-0.4
=-13.26

ProtoKinetix's current Enterprise Value is $5.30 Mil.
ProtoKinetix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProtoKinetix  (OTCPK:PKTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ProtoKinetix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-0.4/6.934524
=-5.77 %

ProtoKinetix's Enterprise Value for the quarter that ended in Mar. 2024 was $6.93 Mil.
ProtoKinetix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProtoKinetix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ProtoKinetix (ProtoKinetix) Business Description

Traded in Other Exchanges
N/A
Address
412 Mulberry Street, Marietta, OH, USA, 45750
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix (ProtoKinetix) Headlines